Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

NCT07670273 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms Immunotherapy

Interventions

DRUG: Trastuzumab Rezetecan
DRUG: Adebrelimab
DRUG: Lenvatinib

Sponsor

Peking Union Medical College Hospital